Ubs Group Ag X4 Pharmaceuticals, Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Ubs Group Ag holds 261,126 shares of XFOR stock, worth $159,286. This represents 0.0% of its overall portfolio holdings.

Number of Shares

261,126

Previous 62,030 320.97%

Holding current value

$159,286

Previous $35,000 397.14%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $107,511 - $171,222	199,096 Added 320.97%	261,126 $174,000
Q2 2024 Aug 13, 2024	SELL	$0.58 - $1.47 $38,891 - $98,569	-67,054 Reduced 51.95%	62,030 $35,000
Q1 2024 May 13, 2024	BUY	$0.72 - $1.46 $92,058 - $186,674	127,859 Added 10437.47%	129,084 $179,000
Q4 2023 Feb 09, 2024	SELL	$0.61 - $0.99 $86,318 - $140,090	-141,506 Reduced 99.14%	1,225 $1,000
Q3 2023 Nov 09, 2023	BUY	$1.03 - $2.02 $144,412 - $283,216	140,206 Added 5552.71%	142,731 $155,000
Q2 2023 Aug 11, 2023	SELL	$0.82 - $2.49 $79,929 - $242,712	-97,475 Reduced 97.48%	2,525 $4,000
Q1 2023 May 12, 2023	BUY	$0.8 - $1.22 $80,000 - $122,000	100,000 New	100,000 $87,000
Q3 2022 Nov 10, 2022	BUY	$0.89 - $1.71 $7,395 - $14,210	8,310 Added 683.95%	9,525 $16,000
Q2 2022 Aug 10, 2022	SELL	$0.88 - $1.91 $42 - $91	-48 Reduced 3.8%	1,215 $1,000
Q1 2022 May 16, 2022	BUY	$1.48 - $2.58 $880 - $1,535	595 Added 89.07%	1,263 $2,000
Q4 2021 Feb 14, 2022	BUY	$1.9 - $5.6 $1,269 - $3,740	668 New	668 $2,000
Q3 2021 Nov 15, 2021	SELL	$4.53 - $6.45 $552 - $786	-122 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$6.49 - $9.56 $25,103 - $36,978	-3,868 Reduced 96.94%	122 $1,000
Q1 2021 May 12, 2021	SELL	$6.63 - $10.28 $75,794 - $117,520	-11,432 Reduced 74.13%	3,990 $34,000
Q4 2020 Feb 11, 2021	BUY	$5.41 - $7.4 $23,116 - $31,620	4,273 Added 38.33%	15,422 $99,000
Q3 2020 Nov 12, 2020	BUY	$6.09 - $9.15 $36,850 - $55,366	6,051 Added 118.69%	11,149 $75,000
Q2 2020 Jul 31, 2020	SELL	$7.98 - $10.44 $33,396 - $43,691	-4,185 Reduced 45.08%	5,098 $48,000
Q1 2020 May 01, 2020	SELL	$6.03 - $11.01 $32,471 - $59,288	-5,385 Reduced 36.71%	9,283 $93,000
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $55,697 - $80,376	5,609 Added 61.92%	14,668 $157,000
Q3 2019 Nov 14, 2019	BUY	$11.06 - $15.75 $86,179 - $122,724	7,792 Added 615.0%	9,059 $115,000
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $13,839 - $23,858	1,101 Added 663.25%	1,267 $19,000
Q1 2019 May 14, 2019	BUY	$15.19 - $22.98 $2,521 - $3,814	166 New	166 $3,000

Others Institutions Holding XFOR

# of Institutions

103

Shares Held

99.9M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $41.9M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account